Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

TG Therapeutics: Add On The Dips As Usual

|Includes: TG Therapeutics, Inc. (TGTX)

If case you are following me on TG Therapeutics, Inc. (NASDAQ:TGTX), this week the company announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 14th International Conference on Malignant Lymphoma (ICML), to be held from June 14-17, 2017, in Lugano, Switzerland.

Several doctors in this field in my network have looked into their pipeline and the responses have essentially been the same. These responses have basically been commuted to me as, "this company is the real deal." Just look at the ORR data that's been released as you investigate what I, and others, already know.

That being said, TG Therapeutics has the potential to be a leading biotech into EOY 2017 - 2018 for those who are patient through the swings and until more coverage and accumulation is executed by the large funds. In order to gain more understanding about this exciting opportunity, please see my earlier article here.

Also, the abstracts were made public and are they are included through the ICML meeting website at Thorough details of the data presentations are outlined below as released by the company.

Oral Presentations:

  • Title: Updated results of a multicenter phase I/Ib study of TGR-1202 in combination with ibrutinib in patients with relapsed or refractory MCL or CLL
    • Abstract Number: 040
    • Presentation Date & Time: Wednesday, June 14, 2017 17:50 CEST
    • Session Title: Chemotherapy-Free Combinations
    • Presenter: Matthew S. Davids, MD, Dana-Farber Cancer Institute
  • Title: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study
    • Abstract Number: 101
    • Presentation Date & Time: Friday, June 16, 2017 11:20 CEST
    • Session Title: Session 7 - Advances in CLL
    • Presenter: Anthony R. Mato, MD, University of Pennsylvania, Abramson Cancer Center
  • Title: Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL
    • Abstract Number: 102
    • Presentation Date & Time: Friday, June 16, 2017 11:35 CEST
    • Session Title: Session 7 - Advances in CLL
    • Presenter: Loretta J. Nastoupil, MD, MD Anderson Cancer Center

Poster Presentation:

  • Title: Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma
    • Abstract Number: 277
    • Presentation Date: Friday, June 16, 2017 (Poster Session)
    • Presenter: Mathew Lunning, DO, University of Nebraska, Omaha, NE

Source: TG Therapeutics website, investor section

Disclosure: I am/we are long TGTX.